Sebastian Szmit: The results of the API-CAT study have been published in NEJM
Sebastian Szmit, Chair of the Council of Cardio-Oncology Study Group on Thrombosis at the European Society of Cardiology, reshared a post by ESMO on LinkedIn:
“NEJM just published the results of the API-CAT study
Everything happened during the ACC25 American College of Cardiology meeting.
Congratulations to Isabelle Mahé for the awesome leadership. I am proud to co-authored together with Prof. Adam Torbicki as the Polish Members of the Steering Committee.
Special thanks to Polish Centres. A great day for cardiooncology.”
Quoting NEJM‘s post:
“Patients with cancer-associated venous thromboembolism (VTE) are at greater risk for recurrent events despite anticoagulant therapy and for bleeding complications than patients with VTE who do not have cancer.
Anticoagulation with a direct oral anticoagulant or low-molecular weight heparin is recommended for an initial period of 6 months.
In this 60-Second Journal Club, NEJM Editorial Fellow Harleen Marwah, summarizes the API-CAT trial, which was recently presented at the American College of Cardiology Annual Scientific Session in Chicago.
The API-CAT trial found that extended anticoagulant therapy with reduced-dose apixaban was noninferior to full-dose apixaban with regard to the prevention of recurrent VTE in patients with active cancer.
Full study: Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism (API-CAT).
More video summaries from ACC25: NEJM YouTube Channel.”
Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism (API-CAT)
Authors: Isabelle Mahé et al.
Proceed to the video attached to the post.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023